2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT Study

BACKGROUND: Multidrug resistant (MDR) Gram-negative bacteria, including metallo-β-lactamase (MBL) producers, pose significant treatment challenges. This study investigated efficacy and safety of aztreonam-avibactam (ATM-AVI) in the treatment of complicated intra-abdominal infection (cIAI) or hospita...

Descripción completa

Detalles Bibliográficos
Autores principales: Carmeli, Yehuda, Cisneros, Jose-Miguel, Paul, Mical, Daikos, Georgios L, Wang, Minggui, Cisneros, Julian Torre, Singer, George, Titov, Ivan, Gumenchuk, Illia, Zhao, Yongjie, Jiménez Rodríguez, Rosa-María, Liang, Lu, Chen, Gang, Pyptiuk, Oleksandr, Aksoy, Firdevs, Rogers, Halley, Wible, Michele, Arhin, Francis, Luckey, Alison, Leaney, Joanne, Pypstra, Rienk, Chow, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676936/
http://dx.doi.org/10.1093/ofid/ofad500.2476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676936/
http://dx.doi.org/10.1093/ofid/ofad500.2476

Ejemplares similares